Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression

doi:10.12998/wjcc.v12.i32.6538

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (661)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

500

Sum=523

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=101

Nov 16, 2024 (publication date) through Dec 31, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Cases. Nov 16, 2024; 12(32): 6538-6542
Published online Nov 16, 2024. doi: 10.12998/wjcc.v12.i32.6538

Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression

Basma M E Mohamed, Mohamed E A Abdelrahim

Basma M E Mohamed, Mohamed E A Abdelrahim, Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 343433, Egypt

Author contributions: Mohamed BME and Abdelrahim MEA were the guarantors of the integrity of the entire study, wrote the manuscript, performed the literature study, conducted the study, had access to the data, and played a role in writing this manuscript.

Conflict-of-interest statement: All authors have no conflicts of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Mohamed E A Abdelrahim, PhD, Professor, Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 23343, Egypt. mohamed.abdelrahim@pharm.bsu.edu.eg

Received: June 11, 2024
Revised: July 25, 2024
Accepted: July 31, 2024
Published online: November 16, 2024
Processing time: 104 Days and 12.5 Hours

Core Tip

Core Tip: Pirfenidone is commonly used to treat idiopathic pulmonary fibrosis (IPF) in its early stages, but it also demonstrated a notable impact on the disease in its advanced stages, having a similar degree of efficacy in individuals with IPF and substantial deterioration of their lung function. It was safe when given to patients with advanced IPF and had a favorable benefit-risk profile, making it an appropriate treatment option for patients with IPF.